Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$53.56 - $87.99
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.75M
Market Cap
$16.38B
Enterprise Value$11.16B
Total Cash (Recent Filing)$2.42B
Total Debt (Recent Filing)$42.41M
Price to Earnings (P/E)19.3
Beta0.50
Next Earnings
Nov 04, 2025EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding195,276,140
10 Day Avg. Volume1,887,962
30 Day Avg. Volume1,746,443
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue2.43
Enterprise Value/Gross Profit2.62
Enterprise Value/Ebitda8.23
Forecast
1Y Price Target
$85.94Price Target Upside-0.88% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Bulls Say, Bears Say
Bulls Say
Long-term StrategyINCY has a clear strategy to address Jakafi LOE in 2028, with several potential launches expected through 2030.
Market Share ExpansionTargeted therapies for MPN patients are expected to significantly grow their market share, with positive initial data validating their approach.
Product ApprovalFDA’s approval of Opzelura for pediatric patients with mild-to-moderate AD improves visibility into modestly incremental growth for this indication.
Sales And PerformanceIncreased confidence in Niktimvo sales estimates is supported by early launch metrics and commercial performance comparisons.
Bears Say
Clinical ExpectationsThe 11–14% separation vs. placebo fell short of higher expectations and trailed efficacy seen with approved biologics and prior PhII povorcitinib data.
Growth ImpactOpzelura's label expansion is expected to have limited impact on near- and longer-term growth due to treatment volume and persistency restrictions.
Incyte News
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $53.56 and its highest was $87.99 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $16.38B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Nov 04, 2025 which is in 33 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 29, 2025. The company reported $1.572 earnings per share for the quarter, beating the consensus estimate of $1.401 by $0.171.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Overvalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.61.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 195,276,140 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.572 in its last earnings report, beating expectations of $1.401. Following the earnings report the stock price went up 10.291%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$85.94 (-0.88% Downside)
$85.94 (-0.88% Downside)
Blogger Sentiment
Bullish
INCY Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 876.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.38%
12-Months-Change
Fundamentals
Return on Equity
24.30%
Trailing 12-Months
Asset Growth
24.87%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation (INCY) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to treat serious diseases, primarily cancer and other hematologic disorders. The company operates in the oncology sector with a strong emphasis on targeted therapies and has a portfolio that includes both approved drugs and a pipeline of investigational products. Key products include Jakafi (ruxolitinib), a treatment for certain types of blood cancers, and other therapeutic candidates aimed at various malignancies and immunological conditions.
INCY Company Deck
INCY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and successful product launches, particularly for Jakafi, Opzelura, and Niktimvo. However, increased R&D expenses and a delay in the regulatory timeline for V617F Phase I data were noted as challenges.View all INCY earnings summariesINCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$85.94
▼(-0.88% Downside)
Technical Analysis
Ownership Overview
15.70% Insiders
22.90% Mutual Funds
0.60% Other Institutional Investors
34.48% Public Companies and
Individual Investors